Expanding The Horizons Of Cellular Therapy: Clinical-Grade Manufacturing Of Difficult-To-Transduce Cells

Lentiviral vectors (LVV) are powerful tools for the ex vivo engineering of human cells and play a crucial role in cellular therapy research and clinical applications. Their high efficiency, stability, and versatility make them indispensable in these fields. However, to ensure successful gene transfer into various hematopoietic cells, pseudotyping with a viral envelope protein is necessary. One common method involves pseudotyping LVV with the vesicular stomatitis virus glycoprotein (VSV-G). This approach has significantly advanced CAR-T cell therapy. However, the low expression of VSV-G's viral receptor, LDLR, in quiescent cells limits its effectiveness in most primary human cells.

In this webinar, we will showcase the pioneering work of Miltenyi R&D and Bioindustry experts, who have become the first to offer BaEV-env LVVs for clinical use. We will present a comprehensive preclinical evaluation of BaEV-LVV-engineered CAR-NK cells and discuss the development of a robust manufacturing platform designed to produce clinical-grade products for commercial and therapeutic use.